Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter

ipharmaservices
Jul 10, 2023
0 min read

Recent Posts

US–Swiss Tariff Cap Impact on Pharma: How the New US–Swiss Tariff Cap Shapes Pharma and Health Security

Switzerland’s new understanding with the US goes beyond a minor tariff tweak and directly touches the country’s role as a pharma and med‑tech hub. Under a November memorandum of understanding, Washing

EU clears Dupixent as first targeted CSU therapy in over a decade | iPharmaCenter

Dupixent (dupilumab) has been approved in the European Union as the first targeted therapy in more than a decade for chronic spontaneous urticaria (CSU) in patients 12 years and older whose disease re

BMS' Breyanzi CAR-T Therapy Approved for Treating Mantle Cell Lymphoma | iPharmaCenter

Bristol Myers Squibb (BMS) has received European Commission approval to extend the use of its CAR T cell therapy Breyanzi (lisocabtagene maraleucel, liso-cel) for adult patients with relapsed or refra

iPharmaCenter

ipharmacenter Consulting services

Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter

Recent Posts

Comments